Skip to main navigation Skip to search Skip to main content

Correlation of Radiological and Pathological Tumor Sizes in Breast Cancer Based on Molecular Subtypes and Accompanying DCIS: A Retrospective Multicenter Study

  • Deniz Esin Tekcan Sanli
  • , Gul Esen Icten
  • , Sibel Kul
  • , Pınar Balci
  • , Nermin Tuncbilek
  • , Levent Celik
  • , Yasemin Kayadibi
  • , Aysenur Oktay
  • , Serap Gultekin
  • , Fusun Taskin
  • , Mustafa Erkin Aribal
  • , Emel Ozveri
  • , Fatma Tokat
  • , Aykut Teymur
  • , Isıl Basara Akin
  • , Gulsah Ozdemir
  • , Davut Can Guner
  • , Seda Aladag Kurt
  • , Ozge Aslan
  • , Aydan Avdan Aslan
  • Ebru Yilmaz
  • Gaziantep University
  • Acibadem Mehmet Ali Aydinlar Universitesi
  • Karadeniz Technical University
  • Dokuz Eylul University
  • Trakya University
  • Istanbul Oncology Hospital
  • Istanbul University - Cerrahpaşa
  • Ege University
  • Gazi University
  • Clinic of Hematology
  • Simav State Hospital
  • Acıbadem Altunizade Hospital

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Purpose: This study aims to compare radiological tumor sizes obtained by mammography (MMG), ultrasonography (US), and magnetic resonance imaging (MRI) with pathological sizes to determine if molecular subtypes and the presence of accompanying ductal carcinoma in-situ (DCIS) affect accuracy. Methods: A total of 559 cases diagnosed with breast cancer in 11 different centers between 2010–2023 were included in the study. The patients' MMG, US, and MRI images were re-evaluated, and radiological findings and tumor sizes were recorded. Histological diagnosis (invasive/in-situ/mixed), receptor status, Ki-67 index, and tumor size were recorded from the pathology reports. Pathologic tumor size (pT) was accepted as the gold standard. Results: The mean pT was 21.1±14.9 (2.7–100) mm in Luminal A tumors, 20.6±12.6 (2–70) mm in Luminal B tumors, 26.3±14.7 (6–80) mm in HER-2(+) tumors, 26.3±14.7 (8–125) mm in triple (-) (TN) tumors. The highest agreement in invasive tumors was obtained with MRI (MRI r:0.831, US r:0.769, MMG r:0.650). In DCIS cases, the agreement was strong with MRI (r:0.770) and intermediate with MMG and US (r:0.517 and r:0.593, respectively). In mixed tumors, agreement was strong with MRI (r:0.817), intermediate with US (r:0.656), and low with MMG (r:0.499). Based on molecular subtypes, MRI had a strong correlation (r>0.7) in both invasive and mixed tumors of all subtypes. US had a strong correlation in all invasive tumors (r>0.7). The correlation was intermediate in Luminal mixed tumors. Mammography had a strong correlation only in invasive Luminal A tumors (r>0.7), and an intermediate correlation in the other invasive tumor subtypes. Regarding mixed tumors, its correlation level was intermediate in Luminal B and TN tumors, and low in Luminal A and HER-2(+) tumors. Conclusion: This multicenter study shows that MRI is the most reliable method for determining preoperative tumor size of invasive and in-situ tumors and all molecular subtypes. The correlation levels of all modalities decreased in pure and mixed DCIS cases, however the difference was minimal with MRI.

Original languageEnglish
Pages (from-to)3511-3518
Number of pages8
JournalAcademic Radiology
Volume32
Issue number6
DOIs
Publication statusPublished - Jun 2025
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Breast cancer
  • Ductal carcinoma in-situ
  • Molecular subtypes
  • Tumor size

Fingerprint

Dive into the research topics of 'Correlation of Radiological and Pathological Tumor Sizes in Breast Cancer Based on Molecular Subtypes and Accompanying DCIS: A Retrospective Multicenter Study'. Together they form a unique fingerprint.

Cite this